Literature DB >> 19651883

Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.

Takeo Sato1, Shigeko Inokuma, Akira Sagawa, Takemasa Matsuda, Tamiko Takemura, Takeshi Otsuka, Yukihiko Saeki, Tsutomu Takeuchi, Tetsuji Sawada.   

Abstract

OBJECTIVE: To elucidate the factors associated with poor prognosis of LEF-induced lung injury in patients with RA.
METHODS: The background and clinical and laboratory features of LEF-induced lung injury were examined and compared between patients who died of and who recovered from it.
RESULTS: Among 22 patients who developed LEF-induced lung injury, 9 died of and 13 recovered from it. The patients who died tended to have pre-existing interstitial pneumonia (8/9 vs 6/13, P = 0.07). The loading and maintenance doses, serum concentration of the LEF metabolite A771726 and administration period did not differ between the groups. Patients who died had more frequently hypoxaemia of <60 Torr and mechanical ventilation, and had a high serum CRP level (19.3 +/- 9.4 vs 10.1 +/- 8.1 mg/dl, P = 0.03) and a low albumin level (2.7 +/- 0.6 vs 3.3 +/- 0.5 g/dl, P = 0.03) at the lung injury onset. The peripheral blood lymphocyte count decreased in both groups at the lung injury onset, and it remained low until fatal outcome, in contrast to a re-increase upon recovery (406 +/- 394 vs 1203 +/- 399/microl, P = 0.006). The main histopathological finding in two autopsied patients was diffuse alveolar damage, in contrast to the alveolitis observed in a biopsied patient who recovered.
CONCLUSIONS: Pre-existing interstitial pneumonia, extremely high serum CRP and low albumin levels, severe hypoxaemia and mechanical ventilation indicated poor prognosis. Peripheral blood lymphocytopenia developed in association with lung injury, and a sustained low lymphocyte count indicated a fatal outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651883     DOI: 10.1093/rheumatology/kep227

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

Review 1.  The Japanese experience with biologic therapies for rheumatoid arthritis.

Authors:  Tsutomu Takeuchi; Hideto Kameda
Journal:  Nat Rev Rheumatol       Date:  2010-09-28       Impact factor: 20.543

2.  Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis.

Authors:  Takeyuki Kanzaki; Kimito Kawahata; Hiroko Kanda; Keishi Fujio; Kanae Kubo; Lisa Akahira; Kazuya Michishita; Toshiki Eri; Kazuhiko Yamamoto
Journal:  Rheumatol Int       Date:  2012-07-18       Impact factor: 2.631

Review 3.  Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.

Authors:  Peter Bb Jones; Douglas Hn White
Journal:  Open Access Rheumatol       Date:  2010-11-03

Review 4.  Drug-Induced Interstitial Lung Disease: A Systematic Review.

Authors:  Sarah Skeoch; Nicholas Weatherley; Andrew J Swift; Alexander Oldroyd; Christopher Johns; Conal Hayton; Alessandro Giollo; James M Wild; John C Waterton; Maya Buch; Kim Linton; Ian N Bruce; Colm Leonard; Stephen Bianchi; Nazia Chaudhuri
Journal:  J Clin Med       Date:  2018-10-15       Impact factor: 4.241

Review 5.  Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.

Authors:  Masayoshi Harigai
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

Review 6.  Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review.

Authors:  Li-Ta Keng; Mong-Wei Lin; Hsien-Neng Huang; Kuei-Pin Chung
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 7.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.